2023

Skip to Main Content

Order by

[P3] Sonti - Factors Affecting Patient Knowledge and Awareness About Neuroendocrine Tumors

Published in 2023 Listed under P

[P4] Sonti - Determinants of Financial Distress in Patients with Neuroendocrine Tumors

Published in 2023 Listed under P

[P5] Yogo - Higher Serotonin Levels from Ileum Neuroendocrine Tumors are associated with Mesenteric Mass Progression

Published in 2023 Listed under P

[P6] Yogo - The use of Antidepressants is associated with Mesenteric Mass Formation of Ileum Neuroendocrine Tumors

Published in 2023 Listed under P

[P7] Gillis - Validity of geographic-level social determinant of health metrics in pancreatic neuroendocrine tumors

Published in 2023 Listed under P

[P8] Gillis - Influence of Social Determinants of Health on Pancreatic Neuroendocrine Tumor Stage at Presentation

Published in 2023 Listed under P

[P9] Rousseau - Contemporary incidence and survival of lung neuroendocrine neoplasms: a population-based study

Published in 2023 Listed under P

[T10] Kennecke - Phase Ib trial of cabozantinib (Cabometyx®) combined with Lu-177 DOTATATE radioligand therapy in patients with advanced, somatostatin receptor positive NETs.

Published in 2023 Listed under T

[T11] Chauhan - NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Published in 2023 Listed under T

[T12] Mailman - Neuroendocrine tumors AI-based clinical trial search tool eases clinical trial discovery for patients and health care professionals

Published in 2023 Listed under T

[T1] Hope - ACTION-1: A randomized Phase Ib/3 trial of RYZ101 compared with SoC in SSTR+ well-differentiated GEP-NET with progression following Lu-177 SSA

Published in 2023 Listed under T

[T2] Demeure - Phase 2 study of nab-sirolimus in patients with welldifferentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Published in 2023 Listed under T

[T3] Lin - Phase 1/2 Trial of Pb-212-VMT-alpha-NET in GI Neuroendocrine Tumors and Pheochromocytoma/ Paraganglioma Previously Treated with Radioligand Therapy

Published in 2023 Listed under T

[T4] Iyer - Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1/2 (PRECISION I)

Published in 2023 Listed under T

[T5] Capdevila - Phase 3 LEVEL trial of 177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Published in 2023 Listed under T

[T6] Halfdanarson - Genetic profiling in the randomized controlled phase 3 COMPOSE trial of 177Lu-edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors

Published in 2023 Listed under T

[T7] Lin - Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors

Published in 2023 Listed under T

[T8] Singh - Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Published in 2023 Listed under T

[T9] McGarrah - Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSV-IFNβ-NIS), with Ipilimumab and Nivolumab, in Patients with Neuroendocrine Carcinoma

Published in 2023 Listed under T